Stability Programs for Leachable Impurities
Instructor:
Wayland Rushing
Product ID: 704685
- Duration: 60 Min
Why Should You Attend:
Leachables are impurities which originate from contact surfaces (typically the final container/closure) of the drug product. As with drug product related impurities it is important to monitor the leachables over the shelf-life of the products to ensure patient safety. Performing leachable stability studies can be challenging and is generally less understood than for typical drug product related impurities. There are several key differences between leachables and drug product related impurities which must be understood in order to design an effective stability program.
This presentation will cover: what are leachables, where they come from, what are the similarities and differences in comparison with drug product related impurities and what are the method and stability requirements.
Learning Objectives:
- Understanding where leachables come from
- Learning the regulatory expectations for leachable stability programs
- Understanding analytical method requirements for leachables
Areas Covered in the Webinar:
Background and Overview of Leachables
- What are extractables and leachables
- Where do they come from
- Why is there concern
How to Design and Implement Leachable Stability Programs
- What are the requirements for leachable stability programs
- How to develop and validate methods for use in leachable stability programs
- Drug product impurities vs. leachable impurities
- Common pitfalls associated with leachable stability programs
Who Will Benefit:
- Drug Development Professionals
- Stability Managers
- CMC Analytical Managers
- Manufacturing
- Quality Assurance
- Regulatory Affairs
- Program Management
Wayland Rushing
Sr Scientific Advisor, ABC Laboratories
Dr. Wayland Rushing is a technical expert in chemistry, manufacturing and controls (CMC) program design, analytical development and regulatory submissions. Over his 15-year career, he has led CMC development programs for a wide array of biopharmaceuticals, including parenterals, inhalation drugs, and other pharmaceuticals with complex delivery systems.
Dr. Rushing is a subject matter expert in HPLC and GC method development and validation, extractables and leachables program design and regulatory submission requirements; has drafted multiple IND and NDA submissions; and assists ABC clients in responding to FDA deficiency letters. He currently serves on Parenteral Drug Association (PDA) advisory committees for Technology Transfer and Elastomeric Closures and Seals Presentation Summary and was co-author of PDA TR 65, Technology Transfer.
More Training By Experts
Refund Policy
Our refund policy is governed by individual products and services refund policy mentioned against each of offerings. However in absence of specific refund policy of an offering below refund policy will be effective.
Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. ComplianceOnline would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange. Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time. On-Demand Recording purchases will not be refunded as it is available for immediate streaming. However if you are not able to view the webinar or you have any concern about the content of the webinar please contact us at below email or by call mentioning your feedback for resolution of the matter. We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email [email protected] call +1-888-717-2436 (Toll Free).
